Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Areteia Therapeutics Inc. currently has 2 pending office actions. These 2 pending office actions involve 2 distinct examiners and 0 distinct art units. The busiest examiner for this portfolio is PURDY, KYLE A, who is responsible for 1 pending office action. This distribution shows that the workload is distributed among the 2 distinct examiners involved in the prosecution efforts.
With 2 pending office actions and 2 distinct examiners, the number of actions is equal to the number of examiners. The data shows 0 distinct art units for these active actions. PURDY, KYLE A is listed as the busiest examiner with 1 pending action, reflecting the scale of the current prosecution queue.
This lack of examiner overlap means that each matter is being treated as an individual file. The involvement of 2 distinct examiners ensures that no individual is managing multiple actions. This structure provides a variety of examiner perspectives for the company despite the 0 distinct art units recorded.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
| VIGIL, TORIANA NICHOLE | 1 | 53.1% | +24.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | — |
| 18988479 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | VIGIL, TORIANA NICHOLE | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | — | §103§112 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18988479 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | VIGIL, TORIANA NICHOLE | — | §102§103DP | Non-Final OA | — | Pending | Dec 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial